


# Capabilities & Highlights



Exosome Diagnostics joined the Bio-Techne family in August 2018 with 100 employees globally and growing! Our clinical labs are in Waltham, Massachusetts and Munich Germany. We have in-house expertise in regulatory, bioinformatics and companion diagnostic assay development. We have also completed large, multi-center, international clinical trials. With over 10 years of experience developing liquid biopsies, we have partnerships with the world's leading Bio-Pharmaceutical companies.

The only single step  
exoRNA + cfDNA  
co-isolation platform  
to achieve high  
sensitivity for rare,  
low frequency  
mutations.

We work with all groups to achieve any goal



**cGMP clinical grade exosome isolation** exoRNA, exoRNA + cfDNA, exoProtein

**Exosome Depletion** Non-relevant exosome

**Exosome Enrichment** Tissue-specific exosome

**RNA-Seq** Whole transcriptome including coding and non-coding

**NGS Panels** All mRNAs, 1400 gene pan-cancer, 170 gene medical oncology

**Portfolio of Assays** EGFR T790M, ALK, ARv7, IDH, & more

**Custom Assay Development** qPCR, dPCR, mutant enrichment PCR, NGS, protein

**Tailored Bioinformatics/AI Tools** Biomarker discovery, variant detection


**Clinical Tests on the Market (LDT)** World's first exosome-based liquid biopsy recommended by NCCN Guidelines for Prostate Cancer Early Detection

Exosomes will empower your projects:  
*from discovery and pre-clinical projects to clinical trials*

- Actively released by all living cells with patient's transcriptome and proteome
- Enables detection of gene rearrangements, splice variants, & RNA editing which are difficult using cfDNA
- Play a role in health and disease
- Not impacted by tumor heterogeneity
- Amenable to frozen storage and highly stable
- More abundant than cfDNA or CTCs
- Provides snapshot of living process

#### Minimal Inputs

Exosomes are more abundant than cfDNA or CTCs enabling volumes as low as 0.5 mL



#### Unlock your Biobank!

Exosomes are highly stable, for >10 yrs at -80 °C




Learn more | [exosomedx.com](http://exosomedx.com) • [BD@exosomedx.com](mailto:BD@exosomedx.com)

# EDDE: Specific Exosome Dx Depletion or Enrichment


EDDE can be tailored for either RNA- or protein-based downstream analyses.

Billions of exosomes are shed into the blood by cells within both **healthy** and **disease/target** tissues. Only a fraction of which will be derived from your **target** tissue/cell type.



## Long RNA-Seq: Whole Transcriptome Biomarker Discovery

**Interrogate Multiple Biofluids**




We can do tissue too!


**Detect the Same RNA Diversity as Tissue**



**Highly Sensitive** with a wide dynamic range



**Simple Collection Requirements**



EDTA




Cost depends on sample number. Excludes bioinformatic analysis.  
Contact [BD.exosome@bio-techne.com](mailto:BD.exosome@bio-techne.com) to get your estimate!



Custom analytics pipeline with tiered data analysis options

## Turn Around Time

We work quickly & efficiently to deliver you high quality results



Service	Process	Turn Around Time*
Long RNA-Seq or OncoSeq Panel	From sample receipt → analysis	4–6 weeks
EDDE Assay Development	Concept → Results	10–12 weeks
qPCR/ddPCR Assay Development	Concept → Pre-validation	6–8 weeks

\* Typical delivery timelines for assays with standard requirements.

Learn more | [exosomedx.com](http://exosomedx.com) • [BD@exosomedx.com](mailto:BD@exosomedx.com)



Global [bio-techne.com](http://bio-techne.com) [info@bio-techne.com](mailto:info@bio-techne.com) TEL +1 612 379 2956 North America TEL 800 343 7475  
Europe | Middle East | Africa TEL +44 (0)1235 529449 China [info.cn@bio-techne.com](mailto:info.cn@bio-techne.com) TEL +86 (21) 52380373

For research use or manufacturing purposes only. Trademarks and registered trademarks are the property of their respective owners.